Details of Moderna's Breakthrough Cancer Vaccine Got Leaked. Its Stock is Plunging.

Moderna's stock fell 25% on Thursday despite positive leaked data showing its cancer vaccine, developed with Merck, reduced melanoma recurrence risk by over 40% when combined with Keytruda. The vaccine also reduced cancer spread risk by 38%. Moderna's stock has risen over 500% this year on vaccine expectations. The trial focused on personalized treatment for melanoma, with experts calling it a landmark in cancer research.

Original reporting
Published Oct 22, 2026, 7:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 7:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Details of Moderna's Breakthrough Cancer Vaccine Got Leaked. Its Stock is Plunging. — source image
Decision brief

The 30-second read

$MRNABearishHigh
01

Why it matters

The unexpected 25% intraday decline highlights market sensitivity to trial news and possible skepticism about commercial prospects.

02

Market read

First disclosure of pivotal trial data; despite positive efficacy, stock reaction creates immediate trading opportunity.

03

What to watch

Potential concerns about regulatory approval timeline, pricing, or manufacturing capacity not disclosed in the leak.

Relevance 8/10Novelty 8/10Timing: same-day intraday

Background

Moderna announced a breakthrough melanoma vaccine in partnership with Merck; leaked Phase 3 results show >40% risk reduction versus Keytruda alone.

Company-level read

Ticker impact

$MRNABearishHigh confidence
Context

Moderna's shares plunged up to 25% after leaked positive Phase 3 data on its melanoma vaccine with Merck.

Expected impact

likely continued pressure as investors reassess valuation after unexpected drop.

Evidence & confidence

The unexpected plunge suggests market doubts about commercial rollout or pricing, creating short‑term downside risk.

$MRKNeutralMedium confidence
Context

Merck is a co‑developer of the vaccine and its immunotherapy Keytruda featured in the leaked trial data.

Expected impact

possible modest downside as investors watch the partnership impact.

Evidence & confidence

Merck's own stock is less directly affected, but the partnership news could temper sentiment.

Market effects

Biotech sector may see heightened volatility as trial data releases can trigger sharp moves regardless of outcome.

U.S. biotech equities could experience broader sell‑off in the afternoon session.

Limited to markets tracking U.S. biotech stocks; no immediate global macro effect.

Counterpoint

The data is highly positive; the price drop may be an overreaction, presenting a buying opportunity.

Key entities

  • Moderna

    Developer of the mRNA cancer vaccine.

  • Merck

    Partner providing Keytruda immunotherapy.

Related articles

$MRKHigh

Why Merck (MRK) Stock Is Down Today

Merck (MRK) shares fell 3.8% after the company discontinued the BELLWAVE clinical program for nemtabrutinib, citing potential risks outweighing benefits in a Phase 3 trial. The decision impacts multiple studies, marking a pipeline setback for the drugmaker. Merck's latest earnings report had shown revenue growth and pipeline activity before this development.

$MRKHigh

Merck wins all 14 U.S. patent reviews against Halozyme

Merck (MSD) won all 14 U.S. patent reviews against Halozyme, securing its Keytruda Qlex cancer immunotherapy's subcutaneous injection technology. The Patent Trial and Appeal Board ruled all challenged claims unpatentable. Keytruda Qlex sales reached $830M in Q3, 9.7% of total Keytruda sales. Halozyme may appeal, and a patent infringement lawsuit is ongoing.